Online inquiry

IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12311MR)

This product GTTS-WQ12311MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12311MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10881MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ11391MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ2778MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-282
GTTS-WQ9413MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Iomab-B
GTTS-WQ135MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ9061MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMC-A12
GTTS-WQ13846MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ11321MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-524
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW